Form 4 for WGS GeneDx Holdings Corp.
Accepted 2026-03-09 00:00:00 ET · period of report 2026-03-06 · accession 0001689575-26-000013 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-09 | 2026-03-06 | WGS | Stueland Katherine | CEO, Dir | A - Grant | $88.11 | +3,404 | 42.1K | +9% | +$299.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2026-03-06 | A | A | 3,404 | $88.11 | 42,087 | D | — | — | (F1) Pursuant to a Subscription Agreement executed on March 6, 2026 between GeneDx Holdings Corp. (the "Issuer") and the reporting person, the reporting person acquired 3,404 shares of the Issuer's Class A common stock directly from the Issuer in an exempt transaction pursuant to Rule 16b-3(d) at a purchase price of $88.11 per share, the closing price of the Issuer's Class A common stock on March 6, 2026. |